IMCR (Immunocore Holdings) Total Receivables: $81.1 Mil (As of Mar. 2026)


IMCR Immunocore Holdings PLC IMCR
76 GF Score
Price $32.03
GF Value $46.16
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Immunocore Holdings Total Receivables?

Immunocore Holdings IMCR +0.28% 76 Total Receivables is $81.1 Mil as of Mar. 2026. GuruFocus rates IMCR with a GF Score™ of 76/100 and a GF Value™ of $46.16 (Possible Value Trap). The stock has 3 warning signs investors should review.

Immunocore Holdings's Total Receivables for the quarter that ended in Mar. 2026 was $81.1 Mil.

Immunocore Holdings Total Receivables Related Terms

Immunocore Holdings Total Receivables Historical Data

* Premium members only.

The historical data trend for Immunocore Holdings's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunocore Holdings Total Receivables Chart

Immunocore Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial 33.53 57.08 61.44 83.10 101.12

Immunocore Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.09 69.76 75.88 101.12 81.07
IMCR
76GF Score
Immunocore Holdings PLC IMCR
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunocore Holdings Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $81.1 Mil mean?
Immunocore Holdings (IMCR) has a Total Receivables of $81.1 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Immunocore Holdings and its competitors.
Is Immunocore Holdings' Total Receivables too high?
Immunocore Holdings' current Total Receivables is $81.1 Mil. Overall, Immunocore Holdings has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Immunocore Holdings' Total Receivables compare to MAZE and DMRA?
Immunocore Holdings' Total Receivables of $81.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Immunocore Holdings and its competitors. Immunocore Holdings's current Total Receivables is $81.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunocore Holdings stock overvalued right now?
Based on GuruFocus' analysis, Immunocore Holdings (IMCR) is currently considered Possible Value Trap. The stock's GF Value™ is $46.16, compared to a current price of $32.03 — trading 30.6% below its estimated fair value. The current Total Receivables is $81.1 Mil. Immunocore Holdings' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Immunocore Holdings (IMCR), the current Total Receivables is $81.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immunocore Holdings (IMCR) Overvalued in 2026?

Based on GuruFocus' analysis, Immunocore Holdings stock appears to be undervalued. The current stock price of $32.03 is trading 30.6% below its estimated GF Value™ of $46.16. GuruFocus considers Immunocore Holdings to be Possible Value Trap.

Key valuation signals for IMCR:

  • Total Receivables: $81.1 Mil
  • GF Value™: $46.16 vs. price of $32.03 (30.6% below fair value)
  • GF Score™: 76/100 with 3 warning signs

No single metric tells the full story. See the IMCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunocore Holdings Business Description

Other Exchanges 6YG:Germany
Address 92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
76GF Score

Get the complete analysis for IMCR

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.03
Price
$46.16
GF Value